 |
| Amsterdam Kat |
This 3-day conference promises to offer 200+ private practice and in-house participants a forum of practical discussions surrounding the leading patent litigation topics in Europe, with a compare-and-contrast method with jurisdictions further afield.
According to the organizers, this internationally recognized summit will provide the necessary practical tools to defend patent litigation challenges for pharma and biotech products, whilst also maximizing litigation strategies to allow for successful IP protection. With the central case law and regulatory updates, this event focuses on the European market and those working within life science IP.
As the agenda also indicates, the following promise to be the highlights of this year’s edition:
- Form a holistic and practical UPC litigation strategy with a cross-industry case law review, a mock trial alongside leading judges and litigators and a pharma and biotech UPC strategy panel.
- Update one’s own pharma and biotech patent litigation strategy with the latest regulatory developments and case law regarding the doctrine of equivalents, second medical use, preliminary injunctions and divisional patent practice.
- Develop a transatlantic understanding of patentability concerns with an Amgen vs Sanofi case law review and an industry-panel concerning the G2/21 EPO Board of Appeals decision.
- Form a global understanding of the patent litigation ecosphere with a panel of judges from the UK, EPO, USA and the UPC.
The IPKat has negotiated a special discount for readers. By using IPKAT at checkout, a 10% discount in the registration fee will be applied. Click here for further details and to register.
Pharma and Biotech Patent Litigation Summit returns to Amsterdam with IPKat readers’ discount
Reviewed by Eleonora Rosati
on
Tuesday, October 10, 2023
Rating:
Reviewed by Eleonora Rosati
on
Tuesday, October 10, 2023
Rating:
Follow the IPKat on LinkedIn 
![[Guest post] EUIPO Second Board of Appeal refers case to Grand Board of Appeal following earlier refusal to register a photograph of a man’s head/face as an EU trade mark](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiUj9v-k3DYaSVMR4lsmKDLHVB5nIoINuvZNbH2TQCelrfaAE9qmGSAQs-plzQ7HnZ7Svk_gRdrIODp0Nat5vpWajduit3xkArNhK76AHhX770RIJ62thfCVI5fnvcXU-5zH4NkUSfPY9FjRMFiK7OKJ7m7YSo2FzhyPSoA8ZWCsxaOXb0bBCoPQA/s72-c/Picture%201.png)
![[Guest post] Benelux Office rules on opposition proceedings prepared by ChatGPT](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi29VY0rNNP1Hqyz8RgB47r4q7fhqQfYHxsEbX_RKmT4KU5Y_vg7vB6dsAW91CidjMfJ38klTvD4mMtZb3QmwFPAHaGF88BPttWSbfYvo7UUg7MpFRTNtEjThmG0QaX2qZFFHSnN71i3YQZSBFC0SL7PgkAlme-XH8cSNWRFbOAOuLr_LMOGcImLQ/s72-c/Screenshot%202024-12-04%20at%2020.45.58.png)
Posts
No comments:
All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.
It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.
Learn more here: http://ipkitten.blogspot.com/p/want-to-complain.html